A randomized phase II chemoprevention trial of 13-cis retinoic acid with or without α tocopherol or observation in subjects at high risk for lung cancer

Karen Kelly, John Kittelson, Wilbur A. Franklin, Timothy C. Kennedy, Catherine E. Klein, Robert L. Keith, Edward C. Dempsey, Marina Lewis, Mary K. Jackson, Fred R. Hirsch, Paul A. Bunn, York E. Miller

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

No chemoprevention strategies have been proven effective for lung cancer. We evaluated the effect of 13-cis retinoic acid (13-cis RA), with or without α tocopherol, as a lung cancer chemoprevention agent in a phase II randomized controlled clinical trial of adult subjects at high risk for lung cancer as defined by the presence of sputum atypia, history of smoking, and airflow obstruction, or a prior surgically cured nonsmall cell lung cancer (disease free, >3 years). Subjects were randomly assigned to receive either 13-cis RA, 13-cis RA plus α tocopherol (13-cis RA/α toco) or observation for 12 months. Outcome measures are derived from histologic evaluation of bronchial biopsy specimens obtained by bronchoscopy at baseline and follow-up. The primary outcome measure is treatment "failure" defined as histologic progression (any increase in the maximum histologic score) or failure to return for follow-up bronchoscopy. Seventy-five subjects were randomized (27/22/26 to obervations/13-cis RA/13-cis RA/α toco); 59 completed the trial; 55 had both baseline and follow-up bronchoscopy. The risk of treatment failure was 55.6% (15 of 27) and 50% (24 of 48) in the observation and combined (13 cis RA plus 13 cis RA/α toco) treatment arms, respectively (odds ratio adjusted for baseline histology, 0.97; 95% confidence interval, 0.36-2.66; P = 0.95). Among subjects with complete histology data, maximum histology score in the observation arm increased by 0.37 units and by 0.03 units in the treated arms (difference adjusted for baseline, -0.18; 95% confidence interval, -1.16 to 0.81; P = 0.72). Similar (nonsignificant) results were observed for treatment effects on endobronchial proliferation as assessed by Ki-67 immunolabeling. Twelve-month treatment with 13-cis RA produced nonsignificant changes in bronchial histology, consistent with results in other trials. Agents advancing to phase III randomized trials should produce greater histologic changes. The addition of α tocopherol did not affect toxicity.

Original languageEnglish (US)
Pages (from-to)440-449
Number of pages10
JournalCancer Prevention Research
Volume2
Issue number5
DOIs
StatePublished - May 2009
Externally publishedYes

Fingerprint

Isotretinoin
Tocopherols
Chemoprevention
Lung Neoplasms
Observation
Histology
Bronchoscopy
Treatment Failure
Outcome Assessment (Health Care)
Confidence Intervals
Phase II Clinical Trials
Sputum
Non-Small Cell Lung Carcinoma
Lung Diseases
Therapeutics
Randomized Controlled Trials
Smoking
Odds Ratio
Biopsy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

A randomized phase II chemoprevention trial of 13-cis retinoic acid with or without α tocopherol or observation in subjects at high risk for lung cancer. / Kelly, Karen; Kittelson, John; Franklin, Wilbur A.; Kennedy, Timothy C.; Klein, Catherine E.; Keith, Robert L.; Dempsey, Edward C.; Lewis, Marina; Jackson, Mary K.; Hirsch, Fred R.; Bunn, Paul A.; Miller, York E.

In: Cancer Prevention Research, Vol. 2, No. 5, 05.2009, p. 440-449.

Research output: Contribution to journalArticle

Kelly, K, Kittelson, J, Franklin, WA, Kennedy, TC, Klein, CE, Keith, RL, Dempsey, EC, Lewis, M, Jackson, MK, Hirsch, FR, Bunn, PA & Miller, YE 2009, 'A randomized phase II chemoprevention trial of 13-cis retinoic acid with or without α tocopherol or observation in subjects at high risk for lung cancer', Cancer Prevention Research, vol. 2, no. 5, pp. 440-449. https://doi.org/10.1158/1940-6207.CAPR-08-0136
Kelly, Karen ; Kittelson, John ; Franklin, Wilbur A. ; Kennedy, Timothy C. ; Klein, Catherine E. ; Keith, Robert L. ; Dempsey, Edward C. ; Lewis, Marina ; Jackson, Mary K. ; Hirsch, Fred R. ; Bunn, Paul A. ; Miller, York E. / A randomized phase II chemoprevention trial of 13-cis retinoic acid with or without α tocopherol or observation in subjects at high risk for lung cancer. In: Cancer Prevention Research. 2009 ; Vol. 2, No. 5. pp. 440-449.
@article{5c498236727544e1b2dd26e57b1aad78,
title = "A randomized phase II chemoprevention trial of 13-cis retinoic acid with or without α tocopherol or observation in subjects at high risk for lung cancer",
abstract = "No chemoprevention strategies have been proven effective for lung cancer. We evaluated the effect of 13-cis retinoic acid (13-cis RA), with or without α tocopherol, as a lung cancer chemoprevention agent in a phase II randomized controlled clinical trial of adult subjects at high risk for lung cancer as defined by the presence of sputum atypia, history of smoking, and airflow obstruction, or a prior surgically cured nonsmall cell lung cancer (disease free, >3 years). Subjects were randomly assigned to receive either 13-cis RA, 13-cis RA plus α tocopherol (13-cis RA/α toco) or observation for 12 months. Outcome measures are derived from histologic evaluation of bronchial biopsy specimens obtained by bronchoscopy at baseline and follow-up. The primary outcome measure is treatment {"}failure{"} defined as histologic progression (any increase in the maximum histologic score) or failure to return for follow-up bronchoscopy. Seventy-five subjects were randomized (27/22/26 to obervations/13-cis RA/13-cis RA/α toco); 59 completed the trial; 55 had both baseline and follow-up bronchoscopy. The risk of treatment failure was 55.6{\%} (15 of 27) and 50{\%} (24 of 48) in the observation and combined (13 cis RA plus 13 cis RA/α toco) treatment arms, respectively (odds ratio adjusted for baseline histology, 0.97; 95{\%} confidence interval, 0.36-2.66; P = 0.95). Among subjects with complete histology data, maximum histology score in the observation arm increased by 0.37 units and by 0.03 units in the treated arms (difference adjusted for baseline, -0.18; 95{\%} confidence interval, -1.16 to 0.81; P = 0.72). Similar (nonsignificant) results were observed for treatment effects on endobronchial proliferation as assessed by Ki-67 immunolabeling. Twelve-month treatment with 13-cis RA produced nonsignificant changes in bronchial histology, consistent with results in other trials. Agents advancing to phase III randomized trials should produce greater histologic changes. The addition of α tocopherol did not affect toxicity.",
author = "Karen Kelly and John Kittelson and Franklin, {Wilbur A.} and Kennedy, {Timothy C.} and Klein, {Catherine E.} and Keith, {Robert L.} and Dempsey, {Edward C.} and Marina Lewis and Jackson, {Mary K.} and Hirsch, {Fred R.} and Bunn, {Paul A.} and Miller, {York E.}",
year = "2009",
month = "5",
doi = "10.1158/1940-6207.CAPR-08-0136",
language = "English (US)",
volume = "2",
pages = "440--449",
journal = "Cancer Prevention Research",
issn = "1940-6207",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - A randomized phase II chemoprevention trial of 13-cis retinoic acid with or without α tocopherol or observation in subjects at high risk for lung cancer

AU - Kelly, Karen

AU - Kittelson, John

AU - Franklin, Wilbur A.

AU - Kennedy, Timothy C.

AU - Klein, Catherine E.

AU - Keith, Robert L.

AU - Dempsey, Edward C.

AU - Lewis, Marina

AU - Jackson, Mary K.

AU - Hirsch, Fred R.

AU - Bunn, Paul A.

AU - Miller, York E.

PY - 2009/5

Y1 - 2009/5

N2 - No chemoprevention strategies have been proven effective for lung cancer. We evaluated the effect of 13-cis retinoic acid (13-cis RA), with or without α tocopherol, as a lung cancer chemoprevention agent in a phase II randomized controlled clinical trial of adult subjects at high risk for lung cancer as defined by the presence of sputum atypia, history of smoking, and airflow obstruction, or a prior surgically cured nonsmall cell lung cancer (disease free, >3 years). Subjects were randomly assigned to receive either 13-cis RA, 13-cis RA plus α tocopherol (13-cis RA/α toco) or observation for 12 months. Outcome measures are derived from histologic evaluation of bronchial biopsy specimens obtained by bronchoscopy at baseline and follow-up. The primary outcome measure is treatment "failure" defined as histologic progression (any increase in the maximum histologic score) or failure to return for follow-up bronchoscopy. Seventy-five subjects were randomized (27/22/26 to obervations/13-cis RA/13-cis RA/α toco); 59 completed the trial; 55 had both baseline and follow-up bronchoscopy. The risk of treatment failure was 55.6% (15 of 27) and 50% (24 of 48) in the observation and combined (13 cis RA plus 13 cis RA/α toco) treatment arms, respectively (odds ratio adjusted for baseline histology, 0.97; 95% confidence interval, 0.36-2.66; P = 0.95). Among subjects with complete histology data, maximum histology score in the observation arm increased by 0.37 units and by 0.03 units in the treated arms (difference adjusted for baseline, -0.18; 95% confidence interval, -1.16 to 0.81; P = 0.72). Similar (nonsignificant) results were observed for treatment effects on endobronchial proliferation as assessed by Ki-67 immunolabeling. Twelve-month treatment with 13-cis RA produced nonsignificant changes in bronchial histology, consistent with results in other trials. Agents advancing to phase III randomized trials should produce greater histologic changes. The addition of α tocopherol did not affect toxicity.

AB - No chemoprevention strategies have been proven effective for lung cancer. We evaluated the effect of 13-cis retinoic acid (13-cis RA), with or without α tocopherol, as a lung cancer chemoprevention agent in a phase II randomized controlled clinical trial of adult subjects at high risk for lung cancer as defined by the presence of sputum atypia, history of smoking, and airflow obstruction, or a prior surgically cured nonsmall cell lung cancer (disease free, >3 years). Subjects were randomly assigned to receive either 13-cis RA, 13-cis RA plus α tocopherol (13-cis RA/α toco) or observation for 12 months. Outcome measures are derived from histologic evaluation of bronchial biopsy specimens obtained by bronchoscopy at baseline and follow-up. The primary outcome measure is treatment "failure" defined as histologic progression (any increase in the maximum histologic score) or failure to return for follow-up bronchoscopy. Seventy-five subjects were randomized (27/22/26 to obervations/13-cis RA/13-cis RA/α toco); 59 completed the trial; 55 had both baseline and follow-up bronchoscopy. The risk of treatment failure was 55.6% (15 of 27) and 50% (24 of 48) in the observation and combined (13 cis RA plus 13 cis RA/α toco) treatment arms, respectively (odds ratio adjusted for baseline histology, 0.97; 95% confidence interval, 0.36-2.66; P = 0.95). Among subjects with complete histology data, maximum histology score in the observation arm increased by 0.37 units and by 0.03 units in the treated arms (difference adjusted for baseline, -0.18; 95% confidence interval, -1.16 to 0.81; P = 0.72). Similar (nonsignificant) results were observed for treatment effects on endobronchial proliferation as assessed by Ki-67 immunolabeling. Twelve-month treatment with 13-cis RA produced nonsignificant changes in bronchial histology, consistent with results in other trials. Agents advancing to phase III randomized trials should produce greater histologic changes. The addition of α tocopherol did not affect toxicity.

UR - http://www.scopus.com/inward/record.url?scp=67650281998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650281998&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-08-0136

DO - 10.1158/1940-6207.CAPR-08-0136

M3 - Article

VL - 2

SP - 440

EP - 449

JO - Cancer Prevention Research

JF - Cancer Prevention Research

SN - 1940-6207

IS - 5

ER -